Analysts’ Opinions Are Mixed on These Healthcare Stocks: NeuroOne Medical Technologies (NMTC), Invivyd (IVVD) and Ligand Pharma (LGND)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on NeuroOne Medical Technologies (NMTC – Research Report), Invivyd (IVVD – Research Report) and Ligand Pharma (LGND – Research Report).

NeuroOne Medical Technologies (NMTC)

In a report released today, Alexander Nowak from Craig-Hallum maintained a Hold rating on NeuroOne Medical Technologies. The company’s shares closed last Friday at $1.53.

According to TipRanks.com, Nowak is a 3-star analyst with an average return of 0.9% and a 44.4% success rate. Nowak covers the Healthcare sector, focusing on stocks such as InfuSystem Holdings, Inc., Accelerate Diagnostics, and Diamedica Therapeutics.

NeuroOne Medical Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $3.33.

See the top stocks recommended by analysts >>

Invivyd (IVVD)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Invivyd, with a price target of $5.00. The company’s shares closed last Monday at $2.07.

According to TipRanks.com, Trucchio has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.5% and a 28.9% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Longboard Pharmaceuticals, and Milestone Pharmaceuticals.

Currently, the analyst consensus on Invivyd is a Moderate Buy with an average price target of $5.00.

Ligand Pharma (LGND)

Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on Ligand Pharma today. The company’s shares closed last Friday at $67.35.

According to TipRanks.com, Hewitt is ranked 0 out of 5 stars with an average return of -5.4% and a 41.8% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Streamline Health Solutions, Champions Oncology, and BioLife Solutions.

Ligand Pharma has an analyst consensus of Strong Buy, with a price target consensus of $119.50, implying a 75.4% upside from current levels. In a report issued on December 13, Benchmark Co. also maintained a Buy rating on the stock with a $95.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NMTC:

• NeuroOne Medical price target raised to $3.33 from $2.20 at Alliance Global
• NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
• Options Volatility and Implied Earnings Moves Today, December 14, 2023
• Is NMTC a Buy, Before Earnings?
• NeuroOne Medical receives FDA 510(k) clearance to market OneRF system